FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3089291112> ?p ?o ?g. }

• W3089291112 endingPage "S972" @default.
• W3089291112 startingPage "S972" @default.
• W3089291112 abstract "AcSé Pembrolizumab is a phase II, non-randomized parallel arm, open-label, multicentric study investigating the efficacy and safety of pembrolizumab monotherapy in patients with rare cancers (NCT03012620). Here we report the results of pembrolizumab in the rare sarcoma cohort. Selected histotypes were all rare sarcomas (incidence <0.2/100,000/year). Main inclusion criteria were age>18, PS≤1, and advanced disease resistant to standard treatment. Patients received pembrolizumab 200 mg IV as a 30-minute infusion on Day 1 of every 21-day cycle for a maximum of 2 years. The primary endpoint was the confirmed objective response rate according to RECIST v1.1. Secondary endpoints included clinical benefit rate, duration of response, progression-free survival (PFS), overall survival (OS), and safety. Five groups of patients were distinguished, namely chordoma, alveolar soft-part sarcoma (ASPS), desmoplastic small round cell tumor (DSRCT), smarca4-malignant rhabdoid tumor (SMBT) and the others. 80 patients with rare sarcomas, including 24 with chordoma, 13 ASPS, 6 DSCRCT, 6 SMBT and 31 with other histotypes, were included from July 2017 to February 2020. The median number of cycles was 5 (range, 1 to 33) with 54 (67.5%) patients who discontinued the trial after a median of 4 cycles. Twenty-eight patients died after a median of 3 cycles (linked to cancer 27, other 1). Best response was PR in 13 patients (16.25%, 95%CI: 8.9 to 26.2%), and SD in 29 (36.25%). The occurrence of best response depended on the histotype, with 2 (8%) responses in chordoma, 5 (39%) in ASPS, 1 (17%) in DSCRCT, 3 (50%) in SMBT, and 2 (6%) in other histotypes (p=0.010). At data cut off, the 1-year PFS rates of the five histotype groups were 35%, 58%, 0, 62.5%, and 8%, with median times of 5.7 months, 14 months, 5, not reached, and 2.7 months respectively (p= 0.00016), while 1-year OS rates were 72%, 90%, 50%, 83% and 40% (p= 0.02). Median survival were only reached for chordoma (20 months), DSRCT (7.4 months), and other histotype group (5.4 months). Pembrolizumab shows high levels of prolonged activity in selected subtypes of rare sarcomas." @default.
• W3089291112 created "2020-10-01" @default.
• W3089291112 creator A5009891337 @default.
• W3089291112 creator A5012166159 @default.
• W3089291112 creator A5015260074 @default.
• W3089291112 creator A5016485718 @default.
• W3089291112 creator A5018331653 @default.
• W3089291112 creator A5020672869 @default.
• W3089291112 creator A5022892812 @default.
• W3089291112 creator A5026883860 @default.
• W3089291112 creator A5031166559 @default.
• W3089291112 creator A5051730942 @default.
• W3089291112 creator A5052673276 @default.
• W3089291112 creator A5053950718 @default.
• W3089291112 creator A5057264839 @default.
• W3089291112 creator A5073713547 @default.
• W3089291112 creator A5078267188 @default.
• W3089291112 creator A5082777483 @default.
• W3089291112 creator A5089578640 @default.
• W3089291112 creator A5090082356 @default.
• W3089291112 creator A5090103193 @default.
• W3089291112 creator A5091721810 @default.
• W3089291112 date "2020-09-01" @default.
• W3089291112 modified "2023-10-17" @default.
• W3089291112 title "1619O High clinical benefit rates of single agent pembrolizumab in selected rare sarcoma histotypes: First results of the AcSé Pembrolizumab study" @default.
• W3089291112 doi "https://doi.org/10.1016/j.annonc.2020.08.1845" @default.
• W3089291112 hasPublicationYear "2020" @default.
• W3089291112 type Work @default.
• W3089291112 sameAs 3089291112 @default.
• W3089291112 citedByCount "11" @default.
• W3089291112 countsByYear W30892911122021 @default.
• W3089291112 countsByYear W30892911122022 @default.
• W3089291112 countsByYear W30892911122023 @default.
• W3089291112 crossrefType "journal-article" @default.
• W3089291112 hasAuthorship W3089291112A5009891337 @default.
• W3089291112 hasAuthorship W3089291112A5012166159 @default.
• W3089291112 hasAuthorship W3089291112A5015260074 @default.
• W3089291112 hasAuthorship W3089291112A5016485718 @default.
• W3089291112 hasAuthorship W3089291112A5018331653 @default.
• W3089291112 hasAuthorship W3089291112A5020672869 @default.
• W3089291112 hasAuthorship W3089291112A5022892812 @default.
• W3089291112 hasAuthorship W3089291112A5026883860 @default.
• W3089291112 hasAuthorship W3089291112A5031166559 @default.
• W3089291112 hasAuthorship W3089291112A5051730942 @default.
• W3089291112 hasAuthorship W3089291112A5052673276 @default.
• W3089291112 hasAuthorship W3089291112A5053950718 @default.
• W3089291112 hasAuthorship W3089291112A5057264839 @default.
• W3089291112 hasAuthorship W3089291112A5073713547 @default.
• W3089291112 hasAuthorship W3089291112A5078267188 @default.
• W3089291112 hasAuthorship W3089291112A5082777483 @default.
• W3089291112 hasAuthorship W3089291112A5089578640 @default.
• W3089291112 hasAuthorship W3089291112A5090082356 @default.
• W3089291112 hasAuthorship W3089291112A5090103193 @default.
• W3089291112 hasAuthorship W3089291112A5091721810 @default.
• W3089291112 hasBestOaLocation W30892911121 @default.
• W3089291112 hasConcept C121608353 @default.
• W3089291112 hasConcept C126322002 @default.
• W3089291112 hasConcept C141071460 @default.
• W3089291112 hasConcept C142724271 @default.
• W3089291112 hasConcept C143998085 @default.
• W3089291112 hasConcept C203092338 @default.
• W3089291112 hasConcept C2777701055 @default.
• W3089291112 hasConcept C2778256501 @default.
• W3089291112 hasConcept C2778629024 @default.
• W3089291112 hasConcept C2779984678 @default.
• W3089291112 hasConcept C2780057760 @default.
• W3089291112 hasConcept C2781190729 @default.
• W3089291112 hasConcept C31760486 @default.
• W3089291112 hasConcept C535046627 @default.
• W3089291112 hasConcept C71924100 @default.
• W3089291112 hasConceptScore W3089291112C121608353 @default.
• W3089291112 hasConceptScore W3089291112C126322002 @default.
• W3089291112 hasConceptScore W3089291112C141071460 @default.
• W3089291112 hasConceptScore W3089291112C142724271 @default.
• W3089291112 hasConceptScore W3089291112C143998085 @default.
• W3089291112 hasConceptScore W3089291112C203092338 @default.
• W3089291112 hasConceptScore W3089291112C2777701055 @default.
• W3089291112 hasConceptScore W3089291112C2778256501 @default.
• W3089291112 hasConceptScore W3089291112C2778629024 @default.
• W3089291112 hasConceptScore W3089291112C2779984678 @default.
• W3089291112 hasConceptScore W3089291112C2780057760 @default.
• W3089291112 hasConceptScore W3089291112C2781190729 @default.
• W3089291112 hasConceptScore W3089291112C31760486 @default.
• W3089291112 hasConceptScore W3089291112C535046627 @default.
• W3089291112 hasConceptScore W3089291112C71924100 @default.
• W3089291112 hasLocation W30892911121 @default.
• W3089291112 hasOpenAccess W3089291112 @default.
• W3089291112 hasPrimaryLocation W30892911121 @default.
• W3089291112 hasRelatedWork W1964812149 @default.
• W3089291112 hasRelatedWork W2965924477 @default.
• W3089291112 hasRelatedWork W3166072320 @default.
• W3089291112 hasRelatedWork W3177224496 @default.
• W3089291112 hasRelatedWork W4220979893 @default.
• W3089291112 hasRelatedWork W4226256362 @default.
• W3089291112 hasRelatedWork W4304690509 @default.
• W3089291112 hasRelatedWork W4322775203 @default.
• W3089291112 hasRelatedWork W4361947625 @default.
• W3089291112 hasRelatedWork W4361954108 @default.

• next